Advances in ovulation trigger strategies.


Journal

Panminerva medica
ISSN: 1827-1898
Titre abrégé: Panminerva Med
Pays: Italy
ID NLM: 0421110

Informations de publication

Date de publication:
Mar 2019
Historique:
entrez: 25 1 2019
pubmed: 25 1 2019
medline: 8 3 2019
Statut: ppublish

Résumé

Ovulation trigger (OT) strategy is a cornerstone in modern patient-tailored in-vitro fertilization treatment, securing the optimal number of mature oocytes retrieved without compromising fertilization, embryo development and euploidy rates. Moreover, the OT strategy is taken into consideration before selecting fresh or frozen embryo transfer (freeze-all) to obtain optimal reproductive outcomes while maintaining a low risk of ovarian hyperstimulation syndrome. Several OT agents have been proposed, however, the most common agents used in modern IVF are human chorionic gonadotropin and gonadotropin-releasing hormone agonist. As no OT agent can be generally recommended for universal use, this review evaluates different OT strategies in different clinical scenarios, discussing both the biological plausibility and the clinical evidence.

Identifiants

pubmed: 30674181
pii: S0031-0808.18.03537-1
doi: 10.23736/S0031-0808.18.03537-1
doi:

Substances chimiques

Chorionic Gonadotropin 0
Fertility Agents, Female 0
Kisspeptins 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

42-51

Auteurs

Carlos Dosouto (C)

Department of Obstetrics, Gynecology and Reproductive Medicine, Santa Creu I Sant Pau Hospital, Puigvert Foundation, Barcelona, Spain - cdosouto@fundacio-puigvert.es.
Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain - cdosouto@fundacio-puigvert.es.

Thor Haahr (T)

The Fertility Clinic Skive Regional Hospital, Skive, Denmark.
Faculty of Health, Aarhus University, Aarhus, Denmark.

Peter Humaidan (P)

The Fertility Clinic Skive Regional Hospital, Skive, Denmark.
Faculty of Health, Aarhus University, Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH